Chin. J. Org. Chem. ›› 2010, Vol. 30 ›› Issue (04): 477-485.     Next Articles

Reviews

HIV整合酶抑制剂的研究进展

郭涤亮1,2,刘冠男1,周宇1,李建1,徐进宜2,蒋华良1,陈凯先1,柳红*,1,2   

  1. (1中国科学院上海药物研究所 新药研究国家重点实验室药物设计和发现中心 上海 201203)
    (2中国药科大学药学院 南京210009)
  • 收稿日期:2009-04-16 修回日期:2009-08-06 发布日期:2010-04-28
  • 通讯作者: 柳红 E-mail:hliu@mail.shcnc.ac.cn
  • 基金资助:

    国家级.863计划

Research Progress in HIV Integrase Inhibitors

Guo Diliang1,2 Liu Guannan1 Zhou Yu1, Li Jian1 Xu Jinyi2 Jiang Hualiang1 Chen Kaixian1 Liu Hong*,1,2   

  1. (1 Drug Discovery and Design Centre, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203)
    (2 School of Pharmacy, China Pharmaceutical University, Nanjing 210009)
  • Received:2009-04-16 Revised:2009-08-06 Published:2010-04-28
  • Contact: Hong Liu E-mail:hliu@mail.shcnc.ac.cn

HIV integrase is one of the three essential enzymes for viral DNA replication and the molecular target of the newly approved anti-AIDS drug raltegravir (MK-0518, Isentress). HIV integrase inhibitors have emerged as a new class of drugs for the treatment of AIDS. In this article, the recent progress of HIV integrase inhibitors is reviewed to provide some useful information for the further research and development of HIV integrase inhibitors.

Key words: HIV, integrase inhibitor, diketoacid, Raltegravir